Vitamin D and immune responses in haematopoietic stem cell transplant

  • Research type

    Research Study

  • Full title

    Vitamin D and immune responses in haematopoietic stem cell transplantation

  • IRAS ID

    225121

  • Contact name

    Alejandro Madrigal

  • Contact email

    a.madrigal@ucl.ac.uk

  • Sponsor organisation

    University College London

  • Duration of Study in the UK

    2 years, 0 months, 0 days

  • Research summary

    Graft-versus-host disease (GvHD) is the most common complication and cause of non-relapse mortality (NRM) after allogeneic HSCT and donor lymphocyte infusion (DLI), affecting nearly half of the patients. Acute GvHD usually happens within the first 3 months after HSCT/DLI and the main organs impaired are skin, gut and liver. Vitamin D has proved to be involved in this process due to its important role in immunity. Steroids are used as immunosuppressive therapy (IS) for GvHD. However, less than 50% of patients respond to them, requiring stronger IS with a subsequent increase in side effects and mortality. Moreover, acute GvHD biomarkers have been found to have a key role in early diagnosis and prognosis but they have never been measured beyond one month post-transplant so their role in long-term follow-up and monitoring response to treatment has never been investigated. Furthermore, studies in chronic GvHD are scarce.

    Studies in patients with asthma showed that patients with lower vitamin D are less responsive to steroids than dose with higher levels. This type of studies have never been performed in the HSCT setting hence the incidence of patients whose vitamin D levels are low hence would benefit from supplementation is unknown.

    Patients who develop GvHD post HSCT / DLI and agree to participle in the study will be recruited and followed up for 6 months. A blood sample will be taken before starting on steroids (D0), 1, 3 and 6 months later to measure vitamin D and biomarkers of GvHD (ST2, elafin and REG3-alpha).

    The study will be carried out in 3 centres across the UK. Samples will be collected from each centre and shipped to Rotherham General Hospital at the end of the study to be processed, with a posterior data analysis.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    17/WM/0325

  • Date of REC Opinion

    21 Aug 2017

  • REC opinion

    Favourable Opinion